{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:19:53Z","timestamp":1782587993219,"version":"3.54.5"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.atherosclerosis.2016.10.017","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T17:31:54Z","timestamp":1478367114000},"page":"128-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom"],"prefix":"10.1016","volume":"255","author":[{"given":"Michael","family":"France","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Capps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Ferns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Seed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cramb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Shoulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Barbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Pottle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Eatough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Bayly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-125X","authenticated-orcid":false,"given":"Bill","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Halcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.atherosclerosis.2016.10.017_bib1","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosissup.2015.02.002","article-title":"Managing homozygous familial hypercholesterolaemia from cradle to grave","volume":"18","author":"Thompson","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib3","unstructured":"Aegerion press release on the availability of lomitapide in the United Kingdom and Europe. Available at:. http:\/\/iraegerioncom\/releasedetailcfm?ReleaseID=980420. 2016."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.10.017_bib4","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.10.017_bib5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in The Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.10.017_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.atherosclerosis.2016.03.009","article-title":"Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study","volume":"248","author":"Raal","year":"2016","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat. Clin. Pract. Cardiovasc Med."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.10.017_bib9","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.biochem.74.082803.133354","article-title":"Structure and physiologic function of the low-density lipoprotein receptor","volume":"74","author":"Jeon","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.ge.24.120190.001025","article-title":"The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein","volume":"24","author":"Hobbs","year":"1990","journal-title":"Annu. Rev. Genet."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.10.017_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","article-title":"Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances","volume":"17","author":"Stefanutti","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.10.017_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/clp.13.79","article-title":"Treatment of homozygous familial hypercholesterolaemia","volume":"9","author":"France","year":"2014","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib14","first-page":"651","article-title":"Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia","volume":"8","author":"Bell","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"issue":"9719","key":"10.1016\/j.atherosclerosis.2016.10.017_bib15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.10.017_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"Chapman","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.10.017_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12265-011-9311-1","article-title":"Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively","volume":"5","author":"Ibrahim","year":"2012","journal-title":"J.\u00a0Cardiovasc Transl. Res."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2015.08.021","article-title":"An update on liver transplantation: a critical review","volume":"66","author":"Neuberger","year":"2016","journal-title":"J.\u00a0Autoimmun."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib19","first-page":"171","article-title":"Long term follow-up after portacaval shunt and internal mammary coronary bypass graft in homozygous familial hypercholesterolemia: report of two cases","volume":"6","author":"Reeves","year":"1990","journal-title":"Can. J. Cardiol."},{"issue":"2\u20133","key":"10.1016\/j.atherosclerosis.2016.10.017_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0021-9150(82)90199-X","article-title":"Treatment of homozygous familial hypercholesterolaemia with portacaval shunt","volume":"41","author":"Forman","year":"1982","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/petr.12561","article-title":"Editorial. Familial Homozygous hypercholesterolemia: when to turn to transplant","volume":"19","year":"2015","journal-title":"Paediatr. Transplant."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1399-3046.2010.01458.x","article-title":"Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late","volume":"15","author":"Malatack","year":"2011","journal-title":"Pediatr. Transpl."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.amjcard.2016.05.042","article-title":"Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia","volume":"118","author":"Martinez","year":"2016","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.10.017_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/petr.12562","article-title":"Liver transplantation as a definitive treatment for familial hypercholesterolemia: a series of 36 cases","volume":"19","author":"Mansoorian","year":"2015","journal-title":"Pediatr. Transpl."},{"issue":"15","key":"10.1016\/j.atherosclerosis.2016.10.017_bib25","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s40265-015-0466-y","article-title":"Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia","volume":"75","author":"Ito","year":"2015","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.10.017_bib26","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"24","key":"10.1016\/j.atherosclerosis.2016.10.017_bib27","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1161\/01.CIR.0000041253.61683.08","article-title":"Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population","volume":"106","author":"Umans-Eckenhausen","year":"2002","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.10.017_bib28","doi-asserted-by":"crossref","first-page":"E1811","DOI":"10.1002\/humu.21348","article-title":"Molecular spectrum of autosomal dominant hypercholesterolemia in France","volume":"31","author":"Marduel","year":"2010","journal-title":"Hum. Mutat."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.10.017_bib29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.110.979450","article-title":"Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children","volume":"123","author":"van der Graaf","year":"2011","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2016.10.017_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jmedgenet-2014-102405","article-title":"Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR\/APOB\/PCSK9 mutations","volume":"51","author":"Futema","year":"2014","journal-title":"J.\u00a0Med. Genet."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2016.10.017_bib31","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib32","unstructured":"British Heart Foundation Data Base available at: http\/\/www.ucl.ac.uk\/ldlr\/LOVDv.1.1.0\/status.php? [Internet]. 2016."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.10.017_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/humu.21438","article-title":"LOVD v.2.0: the next generation in gene variant databases","volume":"32","author":"Fokkema","year":"2011","journal-title":"Hum. Mutat."},{"issue":"9874","key":"10.1016\/j.atherosclerosis.2016.10.017_bib34","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.10.017_bib35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0022-2275(20)41411-7","volume":"33","author":"Salen","year":"1992","journal-title":"Sitosterolemia. J. Lipid Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.10.017_bib36","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1210\/jc.2013-3274","article-title":"Sitosterolemia presenting with severe hypercholesterolemia and intertriginous xanthomas in a breastfed infant: case report and brief review","volume":"99","author":"Park","year":"2014","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcell.2015.00003","article-title":"Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism","volume":"3","author":"Dubland","year":"2015","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.10.017_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","article-title":"Lysosomal acid lipase deficiency\u2013an under-recognized cause of dyslipidaemia and liver dysfunction","volume":"235","author":"Reiner","year":"2014","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.10.017_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/hrt.76.1.84","article-title":"Aortic stenosis in homozygous familial hypercholesterolaemia","volume":"76","author":"Rallidis","year":"1996","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.10.017_bib40","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1161\/CIRCULATIONAHA.106.629808","article-title":"New technology for noninvasive evaluation of coronary artery disease","volume":"115","author":"Di Carli","year":"2007","journal-title":"Circulation"},{"issue":"9678","key":"10.1016\/j.atherosclerosis.2016.10.017_bib41","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib42","article-title":"Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","author":"Board","year":"2014","journal-title":"Heart"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2016.10.017_bib43","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/eurheartj\/eht350","article-title":"Stress echo applications beyond coronary artery disease","volume":"35","author":"Picano","year":"2014","journal-title":"Eur. Heart J."},{"issue":"45","key":"10.1016\/j.atherosclerosis.2016.10.017_bib44","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.10.017_bib45","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"64","author":"Reiner","year":"2011","journal-title":"Rev. Esp. Cardiol."},{"issue":"9753","key":"10.1016\/j.atherosclerosis.2016.10.017_bib46","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2016.10.017_bib47","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Treatment of high blood cholesterol in adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"Pt 6","key":"10.1016\/j.atherosclerosis.2016.10.017_bib48","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1258\/acb.2011.010277","article-title":"Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients","volume":"48","author":"Soran","year":"2011","journal-title":"Ann. Clin. Biochem."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.10.017_bib49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10408363.2013.847897","article-title":"Apo B versus non-HDL-cholesterol: diagnosis and cardiovascular risk assessment","volume":"50","author":"de Nijs","year":"2013","journal-title":"Crit. Rev. Clin. Laboratory Sci."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib50","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.atherosclerosis.2015.10.037","article-title":"Relationship between measurements of non-HDL-cholesterol and LDL-cholesterol in familial hypercholesterolaemia","volume":"245","author":"Abreu","year":"2016","journal-title":"Atherosclerosis"},{"issue":"26","key":"10.1016\/j.atherosclerosis.2016.10.017_bib51","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.10.017_bib52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.10.017_bib53","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1515\/CCLM.2004.114","article-title":"First WHO\/IFCC international reference reagent for lipoprotein(a) for immunoassay\u2013Lp(a) SRM 2B","volume":"42","author":"Dati","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib54","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"20","author":"Kraft","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib55","unstructured":"M. Seed, G.R. Thompson. Neither Lp(a) nor gender influence the risk of cardiovascular disease in homozygous familial hypercholesterolaemia (personal communication)"},{"issue":"9860","key":"10.1016\/j.atherosclerosis.2016.10.017_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2016.10.017_bib57","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.10.017_bib58","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib59","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccl.2015.02.002","article-title":"Lipoprotein apheresis","volume":"33","author":"Moriarty","year":"2015","journal-title":"Cardiol. Clin."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.10.017_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1567-5688(09)71803-3","article-title":"The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption","volume":"10","author":"Julius","year":"2009","journal-title":"Atheroscler. Suppl."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.10.017_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1567-5688(09)71805-7","article-title":"LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience","volume":"10","author":"Keller","year":"2009","journal-title":"Atheroscler. Suppl."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib62","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jacl.2012.03.004","article-title":"Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia","volume":"6","author":"Graesdal","year":"2012","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.10.017_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.transci.2009.05.013","article-title":"26 years of LDL\u2013apheresis: a review of experience","volume":"41","author":"Borberg","year":"2009","journal-title":"Transfus. Apher. Sci."},{"issue":"6510","key":"10.1016\/j.atherosclerosis.2016.10.017_bib64","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/bmj.291.6510.1671","article-title":"Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange","volume":"291","author":"Thompson","year":"1985","journal-title":"Br. Med. J. Clin. Res. Ed."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.10.017_bib65","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2217\/clp.13.57","article-title":"Lipoprotein apheresis for the treatment of familial hypercholesterolaemia","volume":"8","author":"Walji","year":"2013","journal-title":"Clin. Lipidol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.10.017_bib66","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/clp.13.68","article-title":"Lipoprotein apheresis: an update","volume":"8","author":"Julius","year":"2013","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib67","unstructured":"Heart(UK). HEART UK LDL apheresis toolkit available at: www.heartuk.org.uk\/ApheresisToolkit 2014 [updated June 2014]."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib68","unstructured":"Heart(UK). Available at: http:\/\/www.heartuk.org.uk\/health-and-high-cholesterol."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib69","doi-asserted-by":"crossref","first-page":"314283","DOI":"10.1100\/2012\/314283","article-title":"LDL-apheresis: technical and clinical aspects","volume":"2012","author":"Bambauer","year":"2012","journal-title":"ScientificWorldJournal"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib70","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.10.017_bib71","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/MOL.0b013e3283402f53","article-title":"Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe","volume":"21","author":"Thompson","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib73","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1073\/pnas.78.4.2591","article-title":"Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in\u00a0vivo","volume":"78","author":"Thompson","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2016.10.017_bib74","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0022-2275(20)37137-6","article-title":"Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia","volume":"38","author":"Marais","year":"1997","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib75","unstructured":"NHS Blood and Transplant available at: www.nhsbt.nhs.uk."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.10.017_bib76","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.atherosclerosis.2007.06.028","article-title":"A\u00a0dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia","volume":"197","author":"Marais","year":"2008","journal-title":"Atherosclerosis"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2016.10.017_bib77","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.atherosclerosis.2016.10.017_bib78","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2016.10.017_bib79","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc08-0283","article-title":"Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy","volume":"31","author":"Fonseca","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib80","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1038\/ncomms8629","article-title":"Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells","volume":"6","author":"Trabelsi","year":"2015","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2016.10.017_bib81","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2014.02.538","article-title":"Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects","volume":"63","author":"Lambert","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib82","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10557-015-6582-9","article-title":"Update of clinical trials of anti-PCSK9 antibodies","volume":"29","author":"Wu","year":"2015","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med."},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2016.10.017_bib84","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib85","series-title":"Abstract and Poster, 84th European Atherosclerosis Society Congress, Held in Innsbruck, Austria","article-title":"Long-term treatment with evolucomab homozygous familial hypercholesterolemia patients: results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG)","author":"Stein","year":"2016"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.10.017_bib86","doi-asserted-by":"crossref","first-page":"JC31","DOI":"10.7326\/ACPJC-2016-164-6-031","article-title":"Review: PCSK9 inhibitors reduce mortality but increase neurocognitive events in hypercholesterolemia","volume":"164","author":"Santos","year":"2016","journal-title":"Ann. Intern Med."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.10.017_bib87","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1586\/17512433.2016.1162095","article-title":"Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review","volume":"9","author":"Neef","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib88","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacl.2015.05.001","article-title":"Treating homozygous familial hypercholesterolemia in a real-world setting: experiences with lomitapide","volume":"9","author":"Roeters van Lennep","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.10.017_bib89","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.10.017_bib90","doi-asserted-by":"crossref","first-page":"878","DOI":"10.5551\/jat.34777","article-title":"MTP gene variants and response to lomitapide in patients with homozygous familial hypercholesterolemia","volume":"23","author":"Kolovou","year":"2016","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib91","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.atherosclerosis.2015.03.014","article-title":"The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial","volume":"240","author":"Stefanutti","year":"2015","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib92","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosissup.2014.07.005","article-title":"Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia","volume":"15","author":"Cuchel","year":"2014","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib93","unstructured":"Risk Evaluation and Mitigation Strategy for Lomitapide available at:. http:\/\/wwwjuxtapidremsprogramcom\/. 2016."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib94","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib95","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosissup.2015.02.024","article-title":"Pregnancy in homozygous familial hypercholesterolemia\u2013Importance of LDL-apheresis","volume":"18","author":"Blaha","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib96","author":"The Health Foundation"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib97","first-page":"3","article-title":"The risk of cardiovascular disease with second- and third-generation oral contraceptives","volume":"7","author":"Kovacs","year":"2002","journal-title":"Medscape Womens Health"},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib98","doi-asserted-by":"crossref","first-page":"h2135","DOI":"10.1136\/bmj.h2135","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"350","author":"Vinogradova","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib99","series-title":"Contraceptive Choices for Women with Cardiac Disease","year":"2014"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.10.017_bib100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2015.01.007","article-title":"Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia","volume":"239","author":"Lefort","year":"2015","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib101","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacl.2014.11.011","article-title":"Clinical observations and treatment of pediatric homozygous familial hypercholesterolemia due to a low-density lipoprotein receptor defect","volume":"9","author":"Huang","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.10.017_bib102","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1744-9987.2008.00574.x","article-title":"Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years","volume":"12","author":"Palcoux","year":"2008","journal-title":"Ther. Apher. Dial."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.10.017_bib103","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the european liver transplant registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J.\u00a0Hepatol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.10.017_bib104","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/petr.12561","article-title":"Familial homozygous hypercholesterolemia: when to turn to transplant?","volume":"19","author":"Asai","year":"2015","journal-title":"Pediatr. Transpl."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1399-0012.2007.00764.x","article-title":"Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous p.W577R LDL-receptor gene mutation","volume":"22","author":"Schmidt","year":"2008","journal-title":"Clin. Transpl."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.10.017_bib106","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1399-3046.2010.01469.x","article-title":"Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia","volume":"15","author":"Kucukkartallar","year":"2011","journal-title":"Pediatr. Transpl."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib107","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1111\/j.1399-3046.2010.01383.x","article-title":"Preemptive liver transplantation in a child with familial hypercholesterolemia","volume":"15","author":"Maiorana","year":"2011","journal-title":"Pediatr. Transpl."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.10.017_bib108","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00147-004-0791-7","article-title":"Successful living-related liver transplantation for familial hypercholesterolemia in the Middle East","volume":"17","author":"Khalifeh","year":"2005","journal-title":"Transpl. Int."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.10.017_bib109","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00535-006-1765-6","article-title":"Two cases in one family of living donor liver transplantation for homozygous familial hypercholesterolemia","volume":"41","author":"Kawagishi","year":"2006","journal-title":"J.\u00a0Gastroenterol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.10.017_bib110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5551\/jat.14.94","article-title":"Long-term outcome after living donor liver transplantation for two cases of homozygous familial hypercholesterolemia from a heterozygous donor","volume":"14","author":"Kawagishi","year":"2007","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib111","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1432-2277.2003.tb00299.x","article-title":"Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia","volume":"16","author":"Shirahata","year":"2003","journal-title":"Transpl. Int."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib112","series-title":"Use of Aspirin in Children with Cardiac Disease","author":"Buck","year":"2007"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.10.017_bib113","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00246-010-9672-2","article-title":"Antiplatelet therapy in pediatric cardiovascular patients","volume":"31","author":"Li","year":"2010","journal-title":"Pediatr. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.10.017_bib114","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/0974-2069.107236","article-title":"Anti-platelet agents in pediatric cardiac practice","volume":"6","author":"Mohanty","year":"2013","journal-title":"Ann. Pediatr. Cardiol."},{"issue":"Suppl.\u00a06","key":"10.1016\/j.atherosclerosis.2016.10.017_bib115","doi-asserted-by":"crossref","first-page":"887S","DOI":"10.1378\/chest.08-0762","article-title":"Antithrombotic therapy in neonates and children: American College of chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Monagle","year":"2008","journal-title":"Chest"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.atherosclerosis.2016.10.017_bib116","doi-asserted-by":"crossref","first-page":"645S","DOI":"10.1378\/chest.126.3_suppl.645S","article-title":"Antithrombotic therapy in children: the seventh ACCP conference on Antithrombotic and thrombolytic therapy","volume":"126","author":"Monagle","year":"2004","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.10.017_bib117","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00431-014-2485-1","article-title":"Monitoring aspirin therapy in children after interventional cardiac catheterization: laboratory measures, dose response, and clinical outcomes","volume":"174","author":"Schmugge","year":"2015","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib118","unstructured":"The UK Strategy for Rare Diseases available at:. https:\/\/wwwgovuk\/government\/uploads\/system\/uploads\/attachment_data\/file\/260562\/UK_Strategy_for_Rare_Diseasespdf. 2013."},{"issue":"6925","key":"10.1016\/j.atherosclerosis.2016.10.017_bib119","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/bmj.308.6925.367","article-title":"By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?","volume":"308","author":"Law","year":"1994","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.10.017_bib120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"I.\u00a0Reduction in incidence of coronary heart disease","volume":"251","author":"The Lipid Research Clinics Coronary Primary Prevention Trial results","year":"1984","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.10.017_bib121","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","author":"The Lipid Research Clinics Coronary Primary Prevention Trial results","year":"1984","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2016.10.017_bib122","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.CIR.99.8.e1","article-title":"Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting","volume":"99","author":"Gotto","year":"1999","journal-title":"Circulation"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.atherosclerosis.2016.10.017_bib123","first-page":"S1","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and the european atherosclerosis society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2016.10.017_bib124","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.10.017_bib125","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib126","series-title":"International Symposium on Atherosclerosis","article-title":"Decreased cardiovascular events in familial hypercholesterolemic patients treated with mipomersen, an antisense inhibitor of apolipoprotein B translation","author":"Duell","year":"2015"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.10.017_bib127","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2015.09.029","article-title":"Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes","volume":"243","author":"Thompson","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib128","series-title":"What Is an NNT?","author":"Moore","year":"2009"},{"issue":"43","key":"10.1016\/j.atherosclerosis.2016.10.017_bib129","first-page":"2975","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment","volume":"36","author":"Soran","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.10.017_bib130","series-title":"Poster Presented at the Annual Congress of the EAS, May 31st, Innsbruck, Austria","article-title":"Achievement of European Atherosclerosis Society (EAS) targets with lomitapide, a microsomal transfer protein inhibitor in homozygous familial hypercholesterolaemia (HoFH)","author":"Philips","year":"2016"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016314204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016314204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T11:16:52Z","timestamp":1718882212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016314204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":130,"alternative-id":["S0021915016314204"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.10.017","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}